2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
September 24, 2021
Article
Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.
September 22, 2021
Video
Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.
September 21, 2021
Article
Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.
September 20, 2021
Video
Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.
September 09, 2021
Podcast
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
July 15, 2021
Article
Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.
July 12, 2021
Podcast
Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.
June 03, 2021
Article
Siddharth Padia, MD, explaines TheraSphere’s unique mechanism of action and what its approval means in HCC and beyond.
April 22, 2021
Article
Zev A. Wainberg, MD, discusses the role of neoadjuvant chemotherapy in resectable pancreatic cancer, emerging approaches in locally advanced disease, the promise of PARP inhibitors in the metastatic setting, and other future research directions of interest.
April 19, 2021
Video
Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.
April 01, 2021
Video
Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.
March 17, 2021
Article
Richard S. Finn, MD, discusses the data with pembrolizumab and nivolumab that support their utility in hepatocellular carcinoma.
March 12, 2021
Video
Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.
March 06, 2021
Article
The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.
March 05, 2021
Video
Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.
February 19, 2021
Article
Kanwarpal S. Kahlon, MD, discusses the nuances of approaching treatment in ITP, updated guidelines to inform treatment selection, and recent data presented during the 2020 ASH Annual Meeting and Exposition that have the potential to advance the field.
February 18, 2021
Video
Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.
February 15, 2021
Video
Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.
February 12, 2021
Video
Gary J. Schiller, MD, discusses the potential utility of asciminib in chronic myeloid leukemia.
February 08, 2021
Podcast
Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.